Neurocognitive Assessment And Rehabilitation Market By Component (Neurocognitive Assessment Testing, Neurorehabilitation Therapy); By Provider (Rehabilitation Centers, Hospitals & Clinics, Homecare Settings, Physiotherapy Centers); By Demand Pathway (Stroke, Traumatic Brain Injury, Dementia and Cognitive Decline); By Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Neurocognitive Assessment And Rehabilitation Market

Digital assessment, cognitive rehabilitation and longitudinal care reshape the 2026–2032 opportunity

Publication-ready Research Description | Updated on: 25 August 2026

 

MARKET AT A GLANCE

2025 Market Size	2032 Forecast	2026–2032 CAGR	Largest Component	Fastest Provider Segment
USD 15.65 Bn	USD 27.00 Bn	8.1%	Neurorehabilitation Therapy (64.0%)	Homecare Settings (9.1% CAGR)

 

Market size, forecast, segment shares and segment CAGRs are Strategic Market Research estimates. External clinical, epidemiological, regulatory and company facts are separately sourced.

 

Market Positioning: Cognitive Care Is Moving From One-Time Testing to Longitudinal Care

The Global Neurocognitive Assessment And Rehabilitation Market was valued at USD 15.65 billion in 2025 and is projected by Strategic Market Research to reach USD 27.00 billion by 2032, representing a CAGR of approximately 8.1% during 2026–2032. The expansion is being shaped by a shift from episodic cognitive testing toward care pathways that connect screening, formal assessment, rehabilitation, care planning and longitudinal monitoring.

 

Neurocognitive assessment and rehabilitation combines structured evaluation of memory, attention, executive function, language, processing speed and related cognitive domains with interventions designed to restore function, compensate for persistent impairment or improve day-to-day participation. The care pathway can include neuropsychological and computerized assessment, speech-language pathology, occupational therapy, cognitive rehabilitation, multidisciplinary neurorehabilitation and supervised home-based digital programs.

 

Market scope used in this RD. The market is focused on clinically oriented cognitive assessment and cognitive rehabilitation. It does not treat every neurological condition, every physical rehabilitation service or consumer 'brain-training' product as addressable market revenue. Pure musculoskeletal physiotherapy, pharmaceutical treatment and general neurological diagnostics that do not evaluate cognition are outside the core scope. This distinction is important because neurological disease prevalence is much larger than the population that actually receives cognitive assessment or rehabilitation.

The clinical need is substantial, but prevalence must be interpreted carefully. WHO reports that more than 3 billion people live with neurological conditions worldwide and that neurological conditions are the leading cause of ill health and disability. WHO also reports major access gaps: high-income countries can have up to 70 times more neurological professionals per 100,000 people than low- and middle-income countries. [1]

Those neurological figures are not equivalent to the addressable neurocognitive rehabilitation population. The commercial market forms only when impairment is recognized, an appropriate assessment is performed, a patient is referred, services are available and payment or funding supports treatment.

 

CEO implication: The largest value-creation opportunity is not simply 'more cognitive tests.' It is ownership of the assessment-to-care workflow: identification, standardized measurement, referral, intervention, outcome tracking and repeat monitoring.

 

Neurocognitive Assessment And Rehabilitation Market Segmentation and Growth Outlook

By Component

Component	2025 Share	2025 Value	2026–2032 CAGR	Strategic Interpretation
Neurocognitive Assessment Testing	36.0%	USD 5.63 Bn	7.6%	Baseline measurement, impairment documentation, referral support and longitudinal tracking.
Neurorehabilitation Therapy	64.0%	USD 10.02 Bn	8.4%	Recurring clinician-delivered and digital cognitive rehabilitation creates the larger revenue pool.

 

By Provider

Provider	2025 Share	2025 Value	2026–2032 CAGR	Strategic Interpretation
Rehabilitation Centers	34.0%	USD 5.32 Bn	7.9%	Multidisciplinary post-acute and longer-duration care supports the leading share.
Hospitals & Clinics	31.0%	USD 4.85 Bn	7.6%	Key gateway for identification, formal assessment, care planning and referral.
Homecare Settings	20.0%	USD 3.13 Bn	9.1%	Fastest growth as remote supervision and digital therapy extend care beyond facilities.
Physiotherapy Centers	15.0%	USD 2.35 Bn	8.2%	Relevant where neurological programs integrate cognitive and motor rehabilitation; pure musculoskeletal physiotherapy is outside scope.

 

By Geography

Region	2025 Share	2025 Value	2026–2032 CAGR	Strategic Interpretation
North America	39.0%	USD 6.10 Bn	7.6%	Largest market; mature provider base, digital vendors and reimbursable cognitive-care pathways.
Europe	29.0%	USD 4.54 Bn	7.3%	Established stroke and neurological rehabilitation systems support structured assessment and outcome tracking.
Asia Pacific	23.0%	USD 3.60 Bn	9.7%	Fastest regional growth; large need base and service-access gaps favor scalable digital and distributed models.
Latin America	5.0%	USD 0.78 Bn	8.6%	Growth concentrated in larger urban health systems; remote delivery can extend specialist reach.
Middle East & Africa	4.0%	USD 0.63 Bn	8.9%	Selective high-acuity adoption in advanced centers alongside substantial workforce and access constraints.

Note: Segment values are rounded from the 2025 market total and therefore may show minor rounding differences.

 

Component Dynamics: Assessment Creates the Entry Point; Rehabilitation Creates Recurring Utilization

Neurocognitive Assessment Testing accounted for 36.0% of the market, or approximately USD 5.63 billion in 2025, and is projected to expand at 7.6% CAGR. Assessment establishes cognitive baselines, quantifies impairment, supports clinical decision-making and creates the measurement layer required for longitudinal care. Paper-based neuropsychological tools remain important, but digital platforms are changing how tests are administered, scored, documented and repeated across primary care, neurology, rehabilitation and research settings.

Reimbursement can materially influence conversion from screening to formal evaluation. In the United States, Medicare covers a separate Cognitive Assessment & Care Plan service when cognitive impairment is identified; CPT 99483 can be used for a comprehensive cognitive assessment and written care plan, including office/outpatient, residential and telehealth settings. [7]

Neurorehabilitation Therapy held the larger 64.0% share, or approximately USD 10.02 billion in 2025, and is projected to grow at 8.4% CAGR. The revenue advantage comes from repeated therapy sessions rather than one-time testing. Cognitive rehabilitation may involve speech-language pathologists, occupational therapists, psychologists, neuropsychologists and other rehabilitation professionals, with treatment focused on restoring or compensating for impairment in communication, memory, attention, executive function and functional participation.

Digital delivery is expanding the effective treatment window. Patients can perform structured exercises between clinic visits while clinicians review progress and adjust programs. This model can increase therapeutic intensity without requiring an equivalent increase in facility-based session time, but clinical validation, supervision, workflow fit and measurable outcomes remain essential to adoption.

Commercial implication: Assessment vendors compete for clinical workflow and data ownership; rehabilitation vendors compete for repeat engagement. Platforms that connect the two can potentially capture a larger share of patient lifetime value than standalone tests or exercise apps.

 

Provider Economics: Care Is Shifting Toward Hybrid Facility-and-Home Models

Rehabilitation Centers represented the largest provider segment at 34.0% and USD 5.32 billion in 2025. Their advantage is multidisciplinary intensity: stroke and brain-injury patients often need speech-language therapy, occupational therapy, neuropsychology, physical rehabilitation and physician oversight within the same recovery pathway. For this market, the relevant revenue is the cognitive and cognition-linked portion of that program rather than all rehabilitation activity.

Hospitals & Clinics accounted for 31.0% and USD 4.85 billion. Their strategic importance exceeds their direct share because hospitals and specialist clinics frequently control the first cognitive identification, diagnostic work-up, discharge plan and referral. Vendors that integrate with EHRs, fit short clinical workflows and produce documentation that supports follow-up are better positioned than products that operate as isolated tests.

Homecare Settings represented 20.0% and USD 3.13 billion and are projected to grow fastest at 9.1% CAGR. The economic logic is strong: rehabilitation requires repetition, while travel, clinician capacity and patient fatigue limit facility-only care. Hybrid models can extend therapy into the home while retaining clinician oversight and outcome measurement.

Company-reported evidence illustrates the model but should not be generalized beyond the study population. In a Burke Rehabilitation–Constant Therapy pilot involving people recovering from stroke and TBI, participants used home-based digital therapy alongside outpatient care. Constant Therapy reported a 17% average increase in task accuracy, a 64% average improvement in task processing speed and more than 226,000 additional therapeutic exercises completed independently at home. [13]

Physiotherapy Centers accounted for 15.0% and USD 2.35 billion. This segment is relevant only where neurological programs combine motor recovery with cognition, attention, dual-task performance or functional problem-solving. Standalone musculoskeletal physiotherapy should not be counted within the core neurocognitive market.

 

Demand Conversion: Stroke, TBI and Dementia Create Distinct Cognitive-Care Pathways

For pathway-level commercial analysis, Strategic Market Research estimates that stroke-related cognitive care represented approximately 38.0% of the market or USD 5.95 billion in 2025, dementia and cognitive decline represented approximately 36.0% or USD 5.63 billion, and traumatic brain injury represented approximately 26.0% or USD 4.07 billion. These pathway estimates reflect differences in assessment frequency, rehabilitation intensity, duration of care and repeat monitoring rather than epidemiological prevalence alone.

Demand Pathway	2025 Share	2025 Value	2026–2032 CAGR	Commercial Interpretation
Stroke	38.0%	USD 5.95 Bn	8.0%	Large recurring incident pool supports assessment, post-acute rehabilitation and home-based recovery.
Traumatic Brain Injury	26.0%	USD 4.07 Bn	7.4%	Moderate and severe injuries can create prolonged cognitive, behavioral and communication rehabilitation needs.
Dementia and Cognitive Decline	36.0%	USD 5.63 Bn	8.7%	Repeat assessment, care planning, caregiver support and longitudinal monitoring support the fastest pathway growth.

Stroke

Stroke is estimated to account for approximately 38.0% of 2025 market revenue, equivalent to about USD 5.95 billion, and is projected to expand at approximately 8.0% CAGR during 2026–2032. Its commercial position reflects the combination of acute identification, post-stroke cognitive assessment, inpatient rehabilitation, outpatient therapy and continued home-based recovery.

Stroke remains a major demand source because survivors can experience impairments in memory, attention, language, executive function and decision-making. CDC reports that more than 795,000 people have a stroke each year in the United States; about 610,000 are first or new strokes. [4] Not every survivor requires cognitive rehabilitation, but the high incidence creates a recurring assessment and referral pool across acute care, inpatient rehabilitation, outpatient services and home-based recovery.

 

Traumatic Brain Injury

Traumatic Brain Injury is estimated to represent approximately 26.0% of the market, or USD 4.07 billion in 2025, with a projected 7.4% CAGR during 2026–2032. Commercial utilization is concentrated among patients with persistent deficits requiring structured assessment, multidisciplinary rehabilitation, speech-language therapy and repeated functional monitoring.

TBI is another major pathway into neurocognitive assessment and rehabilitation. CDC reports approximately 214,110 TBI-related hospitalizations in the United States in 2020 and 68,663 TBI-related deaths in 2023, while noting that these figures exclude many injuries managed only in emergency departments, primary care, urgent care or without treatment. [5]

Globally, a GBD 2021 analysis estimated 20.84 million incident TBI cases and 37.93 million prevalent cases in 2021. The absolute burden supports sustained demand for assessment of persistent cognitive, behavioral and communication deficits, particularly after moderate and severe injury. [6]

 

Dementia and Cognitive Decline

Dementia and Cognitive Decline is estimated to account for approximately 36.0% of market revenue, equivalent to USD 5.63 billion in 2025, and is projected to record the fastest pathway CAGR of approximately 8.7% during 2026–2032. The higher growth profile reflects multi-year repeat assessment, care planning, caregiver involvement and longitudinal functional monitoring rather than a finite rehabilitation episode.

Dementia strengthens the long-term monitoring side of the market. WHO reports that 57 million people were living with dementia worldwide in 2021, with nearly 10 million new cases each year; more than 60% live in low- and middle-income countries. [3] Unlike stroke or TBI, dementia often creates a multi-year need for repeat assessment, care planning, caregiver support and functional monitoring rather than a finite recovery episode.

WHO also identifies rehabilitation, cognitive stimulation and other non-pharmacological interventions as part of dementia support. This reinforces the market opportunity but also highlights an important evidence requirement: vendors should avoid broad claims of 'improving cognition' unless supported by condition-specific clinical evidence and clearly defined outcomes. [3]

Demand-conversion rule: Epidemiology is the top of the funnel, not market revenue. Commercial demand depends on recognition of impairment, formal assessment, referral, provider capacity, reimbursement/funding, patient adherence and measurable benefit.

 

Regional Growth Frontiers: Infrastructure, Workforce and Reimbursement Determine Conversion

North America: Largest Revenue Pool, With Workflow and Reimbursement as Adoption Levers

North America held 39.0% of the market, valued at USD 6.10 billion in 2025, and is projected to grow at 7.6% CAGR. The United States combines a large stroke/TBI/dementia burden with specialist care, established rehabilitation networks and reimbursement pathways for cognitive assessment and care planning. CMS coverage of CPT 99483, including telehealth, gives cognitive-care vendors a clearer pathway to fit within reimbursable clinical workflows than exists in many markets. [7] Commercially, EHR integration, documentation support and health-system contracting are becoming as important as test performance.

 

Europe: Structured Stroke Pathways Support Outcome Measurement

Europe accounted for 29.0% and USD 4.54 billion in 2025, with a projected 7.3% CAGR. The region benefits from established public rehabilitation systems and structured stroke pathways. In the United Kingdom, the Sentinel Stroke National Audit Programme maintains separate inpatient, community and six-month assessment datasets, reflecting an institutional emphasis on tracking rehabilitation and longer-term outcomes. [8] For vendors, this favors clinically validated tools that can fit standardized care pathways and demonstrate measurable change rather than consumer-style engagement metrics.

 

Asia Pacific: Fastest Growth, Driven by Need and Service-Capacity Gaps

Asia Pacific represented 23.0% and USD 3.60 billion in 2025 and is projected to grow fastest at 9.7% CAGR. The opportunity is not simply population scale. WHO's South-East Asia rehabilitation framework describes access as limited, fragmented and under-prioritized in parts of the region, creating a structural case for scalable assessment, tele-rehabilitation and distributed care models. [2] The highest-value strategies will be those that reduce dependence on scarce specialists while preserving clinical oversight, localization and outcome quality.

 

Latin America: Urban Specialist Concentration Favors Hybrid Delivery

Latin America held 5.0% and USD 0.78 billion in 2025 and is projected to grow at 8.6% CAGR. Adoption is likely to remain concentrated in larger hospital systems and specialist rehabilitation networks, while remote assessment and home-based rehabilitation can extend reach beyond high-density urban centers. The commercial constraint is conversion: technology must fit local payment models, language requirements and clinician availability rather than relying on prevalence alone.

 

Middle East & Africa: Selective High-Acuity Adoption Amid Wide Access Gaps

The Middle East & Africa accounted for 4.0% and USD 0.63 billion in 2025, with a projected 8.9% CAGR. The region combines advanced neurological and rehabilitation centers in selected Gulf markets with substantial access and workforce constraints elsewhere. WHO's global neurology reporting shows how sharply specialist availability differs by income level, supporting a long-term role for lower-cost digital assessment, remote clinician support and home-based rehabilitation. [1]

 

Competitive Innovation: The Market Is Converging Around Workflow, Validation and Longitudinal Data

Competition is fragmented across digital cognitive assessment companies, research-grade cognitive measurement providers, neurophysiological assessment developers and rehabilitation platforms. The key competitive shift is from standalone testing toward workflow ownership. Clinical validation, regulatory positioning, EHR integration, remote delivery, longitudinal tracking, reimbursement fit and the ability to connect assessment results with next-step care increasingly determine enterprise value.

BrainCheck

BrainCheck competes as a digital cognitive assessment and care-planning platform. BrainCheck states that BrainCheck Assess is an FDA Class II, 510(k)-exempt computerized cognitive assessment aid intended to support assessment of cognitive impairment and not to function as a standalone diagnostic tool. [9] In February 2026, the company reported that more than 150 new practices and health systems adopted BrainCheck during 2025, expanding use to more than 500 practices; it also reported 105,000 assessments administered across the platform in 2025. [10]

The more strategically important 2026 development is the move upstream into population identification. On July 30, 2026, BrainCheck launched Population Analytics, which analyzes up to 40 structured EHR factors and produces a prioritized patient registry for clinician review. [11] This shifts the commercial proposition from 'perform a cognitive test' toward 'identify who should be assessed, then manage the cognitive-care workflow.'

 

Linus Health

Linus Health focuses on earlier cognitive identification and longitudinal brain-health management through digital assessment tools including Core Cognitive Evaluation and Anywhere. On March 26, 2026, Linus Health announced a supplier agreement with Provista that expanded access to its digital brain-health solutions for participating physician-practice clients. [12] The strategic significance is distribution: cognitive assessment vendors are increasingly competing through health-system, physician-network and group-purchasing channels rather than direct software sales alone.

 

Constant Therapy Health

Constant Therapy Health is positioned on the rehabilitation side of the pathway, providing adaptive speech, language and cognitive exercises that can be used with clinician-directed therapy and continued at home. Its collaboration with Burke Rehabilitation is commercially relevant because it integrates digital practice into an established outpatient rehabilitation model and demonstrates how hybrid treatment can increase therapy exposure between visits. [13]

 

Cambridge Cognition

Cambridge Cognition competes through validated cognitive measurement, with CANTAB and related digital/voice assessment capabilities serving pharmaceutical trials, academic research and healthcare use cases. Company materials identify CANTAB Mobile as an FDA 510(k) medical device and CANTAB Insight as an FDA-exempt Class II medical device. [14] Its differentiation is strongest where standardized, multilingual cognitive endpoints and sensitivity to change are central to research or clinical evaluation.

 

VoxNeuro

VoxNeuro differentiates through objective neurophysiological measurement rather than behavioral testing alone. The FDA cleared VoxNeuro's Cognitive Function Neuroimaging (cfNI) Software under 510(k) K253015 on June 12, 2026; the device is Class II under the electroencephalograph regulation. [15] The strategic relevance is the potential to complement behavioral assessment with quantified EEG-derived information in selected clinical workflows.

 

Company	Primary Position	2025–2026 Signal	CEO-Level Implication
BrainCheck	Digital assessment + care workflow	150+ new practices in 2025; Population Analytics launched Jul. 2026	Moving upstream from testing into patient identification and EHR workflow.
Linus Health	Digital early detection + longitudinal management	Provista supplier agreement, Mar. 2026	Enterprise distribution and physician-network access are becoming growth levers.
Constant Therapy Health	Digital cognitive/speech rehabilitation	Burke hybrid-care pilot	Home-based therapy can expand treatment intensity and engagement between visits.
Cambridge Cognition	Validated cognitive measurement	Regulated healthcare products + research endpoints	Clinical-trial and healthcare channels reward standardization and sensitivity to change.
VoxNeuro	EEG-derived cognitive assessment	FDA 510(k) clearance, Jun. 2026	Objective physiological measurement may create a differentiated premium assessment layer.

 

Strategic Roadmap Through 2032: Where the Durable Value Pools Are Forming

• Own the referral funnel, not only the test. The highest-value platforms will help providers identify appropriate patients, document medical need, perform standardized assessment, trigger referral and monitor outcomes.

• Build around condition-specific pathways. Stroke, TBI, dementia/MCI and other neurological disorders have different endpoints, recovery patterns and buyer needs. Products that make broad cognition claims without condition-specific evidence will face adoption resistance.

• Treat EHR integration as a commercial feature. Health systems increasingly value workflow fit, documentation and structured longitudinal data. Integration friction can be a larger barrier than test administration time.

• Use hybrid rehabilitation to extend capacity. Home-based digital practice can increase treatment exposure, but successful models should keep clinicians in the loop and demonstrate outcomes rather than simply report app engagement.

• Differentiate with validated outcomes. Sensitivity to change, reproducibility, normative data, language localization, real-world validation and regulatorily appropriate claims are becoming more important as the market matures.

• Design for reimbursement and procurement. US reimbursement illustrates how payment structure can influence adoption. In other markets, enterprise contracts, public health systems, employer/insurer channels or private-pay models may matter more.

• Separate clinical digital health from consumer brain training. Market credibility depends on a clear boundary between clinically oriented assessment/rehabilitation and generalized wellness products that do not support diagnosis, treatment planning or measured functional outcomes.

2032 outlook: The market is likely to reward companies that connect validated assessment, clinically supervised intervention and longitudinal outcomes into one workflow. Technology will expand clinician reach and measurement capacity, but it will complement—not replace—professional diagnosis and rehabilitation planning.

 

CEO Decision Framework: Five Questions That Separate Scalable Platforms From Point Solutions

Question	Why It Matters
1. Who owns the patient-identification step?	Platforms that surface at-risk patients can influence downstream assessment and referral volume.
2. Is the product embedded in clinical workflow?	EHR integration, documentation and care-plan support improve enterprise adoption and retention.
3. Does the solution create recurring utilization?	Rehabilitation, follow-up and longitudinal monitoring can generate repeat engagement beyond an initial test.
4. Are outcomes clinically validated and condition-specific?	Clinical evidence limits overclaiming risk and supports health-system, payer and regulatory credibility.
5. Can the model scale despite workforce shortages?	Remote assessment, asynchronous practice and hybrid care are most valuable where specialist capacity is constrained.

 

Methodology, Scope and Source Transparency

Strategic Market Research estimates. The 2025 market size, 2032 forecast, CAGR, segment shares, segment values and segment growth rates in this RD are Strategic Market Research estimates. The arithmetic has been checked for internal consistency, but the proprietary market-sizing model should be supported on the published page with a concise methodology explaining inclusion/exclusion criteria, primary/secondary research inputs, currency basis and forecast approach.

External facts. Epidemiological, reimbursement, regulatory and company-development statements were cross-checked against government, WHO, peer-reviewed or company-primary sources. Company-reported pilot outcomes and adoption metrics are explicitly presented as company-reported evidence and should not be generalized beyond the disclosed context.

E-E-A-T publication recommendation. For web publication, add a named analyst/reviewer, professional credentials where applicable, 'Last updated: August 2026,' a visible methodology link, source links beside high-impact statistics, and a clear distinction between SMR estimates and third-party facts. This improves transparency, originality and trustworthiness while reducing the appearance of generic, scaled market content.

 

Neurocognitive Assessment And Rehabilitation Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 15.65 Billion
Revenue Forecast in 2032	USD 27.00 Billion
Overall Growth Rate	CAGR of Approximately 8.1% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Component, By Provider, By Demand Pathway, By Geography
By Component	Neurocognitive Assessment Testing, Neurorehabilitation Therapy
By Provider	Rehabilitation Centers, Hospitals & Clinics, Homecare Settings, Physiotherapy Centers
By Demand Pathway	Stroke, Traumatic Brain Injury, Dementia and Cognitive Decline
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Company Usability Profiles	BrainCheck, Linus Health, Constant Therapy Health, Cambridge Cognition, VoxNeuro
Market Drivers	Shift from one-time cognitive testing toward longitudinal cognitive care Large stroke, traumatic brain injury and dementia care pathways Expansion of digital assessment and home-based cognitive rehabilitation Growing integration of cognitive-care tools with EHR and clinical workflows Specialist workforce gaps supporting remote and hybrid care models
Customization Option	Available upon request